Federico II Research
- Heart failure, a condition affecting an estimated 65 million individuals globally, may see improved treatment options thanks to recent research.
- the research,conducted by a team at the University of Naples Federico II,explored the effects of GH replacement on functional and biochemical parameters in HFrEF patients.
- Professor Antonio Cittadino led the research, which was supported by a grant from the German Mercshserono Foundation. The study built upon data from the Tosca register, initially assessing...
Growth Hormone Therapy Shows Promise for Heart Failure Patients
Table of Contents
- Growth Hormone Therapy Shows Promise for Heart Failure Patients
- Growth Hormone Therapy and Heart Failure: Your Questions Answered
- What’s the Latest on growth Hormone and Heart Failure?
- What is Heart Failure with Reduced Ejection Fraction (HFrEF)?
- Who Conducted This Research?
- What Did the Study Investigate?
- Where Was this Research Published?
- What are the Key Findings of the Research?
- Was the Research Supported by Funding?
- What Was the Study Based On?
- Who Led the Research?
- What Are the Future Research Directions?
- What is the Importance of These Findings?
- What is Professor Cittadino’s Background?
- What are the Possible Benefits of Growth Hormone Therapy in heart Failure?
Heart failure, a condition affecting an estimated 65 million individuals globally, may see improved treatment options thanks to recent research. A study published in *JACC-Heart Failure* suggests that growth hormone (GH) replacement therapy could benefit patients with heart failure with reduced ejection fraction (HFrEF).
University of Naples Federico II Research
the research,conducted by a team at the University of Naples Federico II,explored the effects of GH replacement on functional and biochemical parameters in HFrEF patients. The team included professors Alberto Maria Marra, andrea Salzano, Michele Arcopinto, and Dr. Roberta D’assanto. The findings prompted an accompanying editorial titled “Reevaluating Growth Hormone Therapy in HFrEF: More Questions Than Answers?”
Study details and Funding
Professor Antonio Cittadino led the research, which was supported by a grant from the German Mercshserono Foundation. The study built upon data from the Tosca register, initially assessing the clinical importance of growth hormone deficiency in heart failure. Researchers believe the results pave the way for targeted therapies addressing anabolic deficits in heart failure patients.
Future Research Directions
The study’s findings raise several questions for future inquiry. Researchers aim to determine if growth hormone replacement therapy can improve long-term outcomes, such as hospitalization rates and survival. They also plan to explore the potential benefits of multiple hormone replacement therapies for heart failure patients with hormonal comorbidities, acknowledging the systemic nature of the disease beyond the cardiovascular system.
Professor Cittadino’s Appointments
Professor Cittadino is the director of the Department of Integrated Activities of Internal Medicine and Clinical Complexity at the AOU – Federico II University Hospital. He also leads working groups on cardiac insufficiency for the European Federation of Internal Medicine (FIM) and the Italian Society of Internal Medicine (SIMI). Recently, he was appointed president of the Italian Association of Preventive Cardiology Rehabilitation (ICPR) and adjunct professor at Alfaisal University in Saudi Arabia.
Growth Hormone Therapy and Heart Failure: Your Questions Answered
Are you curious about the connection between growth hormone therapy and heart failure? This article delves into recent research, providing clear answers to your questions. We’ll explore the latest findings, the researchers involved, and the potential impact on heart failure patients.
What’s the Latest on growth Hormone and Heart Failure?
Recent research suggests that growth hormone (GH) replacement therapy could be a promising treatment for heart failure patients. A study published in JACC-Heart Failure indicates potential benefits, particularly for those with heart failure with reduced ejection fraction (HFrEF).
What is Heart Failure with Reduced Ejection Fraction (HFrEF)?
[Featured Snippet Candidate] HFrEF is a type of heart failure. It means the heart’s left ventricle doesn’t squeeze (pump) hard enough, so less oxygen-rich blood is pumped out to the body.
Who Conducted This Research?
The research was conducted by a team at the University of Naples federico II. The team included:
Professors Alberto Maria Marra
Andrea salzano
Michele Arcopinto
Dr. Roberta D’assanto
What Did the Study Investigate?
The study explored the effects of GH replacement on functional and biochemical parameters in patients with HFrEF.
Where Was this Research Published?
The study was published in JACC-Heart Failure.
What are the Key Findings of the Research?
The research suggests that growth hormone replacement therapy could benefit patients with HFrEF.The study’s findings have prompted further investigation and raise several questions for future inquiry.
Was the Research Supported by Funding?
Yes,the research was supported by a grant from the German Mercshserono Foundation.
What Was the Study Based On?
the study built upon data from the Tosca register.
Who Led the Research?
Professor Antonio Cittadino led the research.
What Are the Future Research Directions?
[Featured Snippet Candidate] Researchers aim to determine if growth hormone replacement therapy can improve long-term outcomes, such as:
Hospitalization rates
Survival
they also plan to explore the potential benefits of multiple hormone replacement therapies for heart failure patients with hormonal comorbidities.
What is the Importance of These Findings?
Researchers believe the results pave the way for targeted therapies addressing anabolic deficits in heart failure patients.
What is Professor Cittadino’s Background?
Professor Cittadino is:
Director of the Department of Integrated Activities of Internal Medicine and Clinical Complexity at the AOU – Federico II university Hospital.
Leads working groups on cardiac insufficiency for the European Federation of Internal Medicine (FIM) and the Italian Society of Internal Medicine (SIMI).
* Recently appointed president of the Italian Association of Preventive Cardiology Rehabilitation (ICPR) and adjunct professor at Alfaisal University in Saudi Arabia.
What are the Possible Benefits of Growth Hormone Therapy in heart Failure?
The research suggests potential benefits. While the exact benefits are still under investigation, the study indicates that GH replacement might improve the functional and biochemical parameters in patients with HFrEF. Further research aims to determine if it can improve long-term outcomes like hospitalization rates